Among C3 (CML), imatinib is the first targeted antitumor drug that was first approved by the FDA in 2001 for patients with BCR-ABL–positive CML [10,11,28,29,71]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.